Last reviewed · How we verify
NCT04927598
Predictors and Prognostic Factors of Gullian Barrie Syndrome Outcome
trial testing plasmapheresis in Guillain-Barre Syndrome in 62 participants. Completed in 1 April 2022.
15 October 2021
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 62 |
| Start date | 20 October 2020 |
| Primary completion | 15 October 2021 |
| Estimated completion | 1 April 2022 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- plasmapheresis — full drug profile →
Conditions studied
- Guillain-Barre Syndrome — all drugs for Guillain-Barre Syndrome →
Sponsor
Assiut University
Who can join
10 and older, any sex, with Guillain-Barre Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to identify clinical and biological determinants and factors that predict outcome including primary outcome (percentage of changes in clinical scales pre- and after 3 months ) and secondary outcome depending on neurophysiologiacal studies and prognostic factors in individual patients with Guillain-Barre syndrome i individuals managed by plasmapheresis and IVIG immunoglobulin . This information will be used to understand the diversity in clinical presentation and response to treatment of GBS.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Early electrophysiological study variants and their relationship with clinical presentation and outcomes of patients with Guillain-Barré syndrome.
Khedr EM, Shehab MM, Mohamed MZ, Mohamed KO. · · 2023 · cited 4× · PMID 37634022 · DOI 10.1038/s41598-023-41072-x
Verify or expand the search:
- PubMed search for NCT04927598
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of plasmapheresis
Trials testing the same drug.
- NCT03501680 — Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis. · Phase 4 · unknown
- NCT03965559 — The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant · completed
Other recruiting trials for Guillain-Barre Syndrome
Currently open trials in the same condition.
- NCT07020819 — An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barr · Phase 3 · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04927598 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 8 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04927598.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing